JonesTrading analyst Justin Walsh has reiterated their bullish stance on YMAB stock, giving a Buy rating today.
Justin Walsh has given his Buy rating due to a combination of factors that highlight the potential of Y-Mabs Therapeutics. Despite a recent decrease in the price target from $23 to $18, Walsh maintains a positive outlook on the company’s future, particularly due to its promising radiopharmaceutical platform. The company’s pipeline, especially the SADA PRIT platform, is expected to drive significant revenue growth in the coming years, with projections indicating that it could account for a substantial portion of the company’s revenue by FY34.
Furthermore, the upcoming updates and data readouts from ongoing trials, such as the GD2-SADA Phase I trial, are anticipated to showcase the company’s innovative capabilities and potential for competitive advantages in the oncology sector. Although the current revenue guidance for FY25 is lower than previously estimated, Walsh believes that patient investors will be rewarded as the company’s pipeline matures and delivers differentiated assets.
According to TipRanks, Walsh is an analyst with an average return of -5.8% and a 27.10% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Y-Mabs Therapeutics, Perspective Therapeutics, and Achieve Life Sciences.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $21.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com